OpenEvidence, the ChatGPT for doctors, raises $200M at $6B valuation (techcrunch.com)

OpenEvidence, a startup that markets itself as a “ChatGPT for doctors,” raised $200 million at a $6 billion valuation — only three months after a $210 million raise that valued it at $3.5 billion — underscoring intense investor interest in vertical AI. The round was led by Google Ventures with participation from Sequoia, Kleiner Perkins, Blackstone, Thrive, Coatue, Bond and Craft. Founded in 2022, OpenEvidence has quickly scaled: verified medical professionals can use its ad-supported tool for free, and reported clinical consultations have nearly doubled to about 15 million per month since July. Technically, OpenEvidence is trained on authoritative medical literature including JAMA and the New England Journal of Medicine and aims to surface existing medical knowledge to speed clinical decision‑making. That focus on curated, peer‑reviewed sources is a strength for clinical reliability, but the ad-supported model and rapid deployment raise practical concerns around conflicts of interest, provenance, liability and regulatory oversight (FDA/HIPAA). For the AI/ML community, the deal highlights massive demand for domain-specific LLMs that integrate vetted corpora and clinician workflows — and it spotlights the tradeoffs between scaling product reach and ensuring safety, transparency and governance in high‑stakes healthcare applications.